To Screen—or not to screen for for advanced steatotic liver disease that’s the question? Our new @lancetgastrohep.bsky.social review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria @Stine Johansen authors.elsevier.com/c/1lRV98nByr...

New Review - Screening for advanced steatotic liver disease www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social

APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol" www.nature.com/articles/s41... #Liversky

Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more! www.nature.com/nrgastro/vol...

🧪 New findings published in @jhepatology.bsky.social JHEP reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect histological disease activity in MASLD/MASH patients in response to treatment.   doi.org/10.1016/j.jh...

Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency?   Proud of being part of this project - Deep Visual Proteomics at single cell level 👉in @nature.com   www.nature.com/articles/s41...

Check out the “Steatotic Liver Disease Burden Paradox “ pubmed.ncbi.nlm.nih.gov/39639157/

Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️ Over 60% with MetALD/ALD and 38% with MASLD change subclass. This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐 Link: www.cghjournal.org/article/S154...

We made the cover of Hepatology 👏👏 @aleksanderkrag.bsky.social #LiverSky journals.lww.com/hep/fulltext...

In today’s #readoftheweek📚 learn why accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with #steatoticliverdisease & when designing clinical trials. Read now: www.jhep-reports.eu/article/S258... 🙏 @aleksanderkrag.bsky.social @majathiele.bsky.social et al.

#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.! easl.eu/easl-studio-...

AlbTrial Update 🏥 70 out of 240 included But what is AlbTrial? AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis. 🔗 bmjopen.bmj.com/content/bmjo... 🧵below Annual General Assembly in MicrobPredict #liversky #cirrhosis

What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease? @aleksanderkrag.bsky.social and colleagues discuss… www.thelancet.com/journals/lan... #GastroSky #MedSky

Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD - MASLD VS MetALD/ALD is not 10:1 - more likely 1:1😳 - The Lancet Gastroenterology & Hepatology www.thelancet.com/journals/lan...

Joined a great meeting in Helsinki recently and had the pleasure of seeing but not understanding the new nomenclature of Steatotic liver disease in Finnish😀

2025 is the perfect year to take your career to the next level🚀 There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force. Apply by 20 January: easl.eu/leadership25 #LiverSky

Two days of finalizing the narrative and recommendations of the second EASL @thelancet.bsky.social Commission in Geneva. Now we write the report! @aleksanderkrag.bsky.social

EASL Governing Board meeting - working for the community❤️ 👉SLD and LCS summits 👉EASL schools / what and where? 👉EiC @JHepatology @JHEP_Reports new initiatives🤩 👉 X vs @bluesky ? 👉AI Task Force 👉#EASLCongress 2025 Amsterdam 👉Register grants 👉Global collaboration

@EASL @AASLD MASTERCLASS in beautiful Savannah ❤️ Gathering of next generation of leaders in hepatology🤩🤩 👉team science 👉building a team Networking

Ever heard about the “Steatotic Liver Disease burden paradox”? Check it out 👇👇👇 Perspective in @natureportfolio.bsky.social rdcu.be/d2wcV

Remember deadline for abstract EASLCongress 2025 in Amsterdam December 3rd !!

After a successful #TLM24 AASLD in San Diego - thanks Ray Kim and Paul Kwo for a fantastic hospitality at @stanfordpress.bsky.social